Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Novanta Announces Financial Results for the First Quarter 2022

NOVT

  • First Quarter 2022 GAAP Revenue increased 26% to $204 million
  • First Quarter 2022 GAAP Consolidated Net Income of $18.8 million
  • First Quarter 2022 GAAP Diluted Earnings Per Share of $0.53
  • First Quarter 2022 Adjusted Earnings Per Share increased 26% to $0.73
  • First Quarter 2022 Adjusted EBITDA increased 33% to $43.6 million

Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the first quarter 2022.

Financial Highlights

Three Months Ended

(In millions, except per share amounts)

April 1,

April 2,

2022

2021

GAAP

Revenue

$

204.2

$

162.6

Operating Income

$

24.3

$

11.1

Consolidated Net Income

$

18.8

$

11.3

Diluted EPS

$

0.53

$

0.32

Non-GAAP*

Adjusted Operating Income

$

33.5

$

22.8

Adjusted Diluted EPS

$

0.73

$

0.58

Adjusted EBITDA

$

43.6

$

32.7

*Reconciliations of GAAP to non-GAAP financial measures, as well as definitions for the non-GAAP financial measures included in this press release and the reasons for their use, are presented below.

“Novanta delivered strong first quarter results, with double-digit growth for sales, bookings, and profit,” said Matthijs Glastra, Chair and Chief Executive Officer of Novanta. “Customer demand continues to be robust across our advanced industrial and medical application areas, with customer orders up 11% year over year, giving us a new record level of backlog at $586 million. These results were achieved with a strong organic growth engine, further supported with strongly performing recent acquisitions. Our teams were able to deliver this impressive outcome all while navigating through the continued difficult macroeconomic environment.”

First Quarter

During the first quarter of 2022, Novanta generated GAAP revenue of $204.2 million, an increase of $41.6 million, or 25.6%, versus the first quarter of 2021. The Company’s acquisition activities resulted in an increase in revenue of $32.8 million, or 20.2%, compared to the first quarter of 2021. Changes in foreign currency exchange rates year over year negatively impacted our revenue by $3.3 million, or 2.0%, during the first quarter of 2022. Our year-over-year Organic Revenue Growth, which excludes the net impact of acquisitions and changes in foreign currency exchange rates, was an increase of 7.4% for the first quarter of 2022 (see “Organic Revenue Growth” in the non-GAAP reconciliations below).

In the first quarter of 2022, GAAP operating income was $24.3 million, compared to $11.1 million in the first quarter of 2021. GAAP consolidated net income was $18.8 million in the first quarter of 2022, compared to $11.3 million in the first quarter of 2021. GAAP diluted earnings per share (“EPS”) was $0.53 in the first quarter of 2022, compared to $0.32 in the first quarter of 2021.

Adjusted Diluted EPS was $0.73 in the first quarter of 2022, compared to $0.58 in the first quarter of 2021. The Company ended the first quarter of 2022 with 35.8 million diluted weighted average shares outstanding. Adjusted EBITDA was $43.6 million in the first quarter of 2022, compared to $32.7 million in the first quarter of 2021.

Operating cash flow for the first quarter of 2022 was $11.3 million, compared to $23.3 million in the first quarter of 2021. The Company completed the first quarter of 2022 with approximately $417.5 million of total debt and $98.8 million of total cash. Net Debt, as defined in the non-GAAP reconciliation below, was $324.4 million.

Financial Guidance

“We expect to see strong double-digit growth in the second quarter, despite the global backdrop of supply chain challenges, inflationary pressures, continued COVID disruptions in China, and the war in the Ukraine,” said Matthijs Glastra. “Our customer demand remains exceptionally strong across both medical and advanced industrial end markets. We continue to be confident in our strategic positioning, in the capabilities and commitment of our teams, and our product innovation.”

For the second quarter of 2022, the Company expects GAAP revenue of approximately $205 million to $213 million, demonstrating reported growth of 22% to 27%. The Company expects Adjusted Gross Profit Margin to be in the range of 45.0% to 46.0%. The Company expects Adjusted EBITDA to be in the range of $42 million to $44 million and Adjusted Diluted EPS to be in the range of $0.69 to $0.73. The Company’s guidance assumes no significant changes in foreign exchange rates.

Novanta provides earnings guidance on a non-GAAP basis and does not provide earnings guidance on a GAAP basis, with the exception of GAAP revenue guidance. A reconciliation of the Company’s forward-looking Adjusted Gross Profit Margin, Adjusted EBITDA and Adjusted EPS guidance to the most directly comparable GAAP financial measures is not provided because of the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, including future changes in the fair value of contingent considerations; significant discrete income tax expenses (benefits); divestitures and related expenses; acquisitions and related expenses; impact of purchase price allocations for recently completed acquisitions; gains and losses from sale of real estate assets; costs related to product line closures; intangible asset impairment charges and related asset write-offs; future restructuring expenses; foreign exchange gains/(losses); benefits or expenses associated with the completion of tax audits; and other charges reflected in the Company’s reconciliation of historical non-GAAP financial measures, the amounts of which, based on past experience, could be material. For additional information regarding Novanta’s non-GAAP financial measures, see “Use of Non-GAAP Financial Measures” below.

Conference Call Information

The Company will host a conference call on Tuesday, May 10, 2022 at 10:00 a.m. ET to discuss these results and to provide a business update. To access the call, please dial (888) 346-3959 prior to the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company’s website at www.novanta.com.

A replay of the audio webcast will be available approximately three hours after the conclusion of the call in the Investor Relations section of the Company’s website at www.novanta.com. The replay will remain available until Monday, July 4, 2022.

Use of Non-GAAP Financial Measures

The non-GAAP financial measures used in this press release are Organic Revenue Growth, Adjusted Gross Profit, Adjusted Gross Profit Margin, Adjusted Operating Income and Operating Margin, Adjusted Income before Income Taxes, Adjusted Income Tax Provision/(Benefit) and Effective Tax Rate, Adjusted Consolidated Net Income, Adjusted Diluted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, Free Cash Flow as a Percentage of Consolidated Net Income, and Net Debt.

The Company believes that these non-GAAP financial measures provide useful and supplementary information to investors regarding the operating performance of the Company. It is management’s belief that these non-GAAP financial measures would be particularly useful to investors because of the significant changes that have occurred outside of the Company’s day-to-day business in accordance with the execution of the Company’s strategy. This strategy includes streamlining the Company’s existing operations through site and functional consolidations, strategic divestitures and product line closures, expanding the Company’s business through significant internal investments, and broadening the Company’s product and service offerings through acquisition of innovative and complementary technologies and solutions. The financial impact of certain elements of these activities, particularly acquisitions, divestitures, and site and functional restructurings, is often large relative to the Company’s overall financial performance and can adversely affect the comparability of its operating results and investors’ ability to analyze the business from period to period.

The Company’s Adjusted EBITDA, Organic Revenue Growth and Adjusted Gross Margin are used by management to evaluate operating performance, communicate financial results to the Board of Directors, benchmark results against historical performance and the performance of peers, and evaluate investment opportunities, including acquisitions and divestitures. In addition, Adjusted EBITDA, Organic Revenue Growth and Adjusted Gross Margins are used to determine bonus payments for senior management and employees. The Company also uses Adjusted Diluted EPS as a measurement for performance-based restricted stock units issued to certain executives. Accordingly, the Company believes that these non-GAAP financial measures provide greater transparency and insight into management’s method of analysis.

Non-GAAP financial measures should not be considered as substitutes for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on the Company’s reported results and, therefore, should not be relied upon as the sole financial measures to evaluate the Company’s financial results. The non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial measures. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures as provided in the tables accompanying this press release.

Safe Harbor and Forward-Looking Information

Certain statements in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are based on current expectations and assumptions that are subject to risks and uncertainties. All statements contained in this news release that do not relate to matters of historical fact should be considered forward-looking statements, and are generally identified by words such as “expect,” “intend,” “anticipate,” “estimate,” “believe,” “future,” “could,” “should,” “plan,” “aim,” and other similar expressions. These forward-looking statements include, but are not limited to, statements regarding anticipated financial performance and financial position, including our financial outlook for the second quarter; statements regarding the COVID-19 pandemic; expectations for our end markets and market position; expectations regarding our ability to mitigate supply chain disruptions; inflationary pressures; expectations regarding the benefits of recent acquisitions; expectations regarding our design win and customer order activities and long-term prospects in our medical and advanced industrial end-markets; and other statements that are not historical facts.

These forward-looking statements are neither promises nor guarantees, but involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, but not limited to, the following: economic and political conditions and the effects of these conditions on our customers’ businesses, capital expenditures and level of business activities; risks associated with the COVID-19 pandemic and other events outside our control; our dependence upon our ability to respond to fluctuations in product demand; our ability to continually innovate, introduce new products timely, and successfully commercialize our innovations; failure to introduce new products in a timely manner; customer order timing and other similar factors beyond our control; disruptions or breaches in security of our and our third-party providers’ information technology systems; our failure to comply with data privacy regulations; changes in interest rates, credit ratings or foreign currency exchange rates; risks associated with our operations in foreign countries; our increased use of outsourcing in foreign countries; risks associated with increased outsourcing of components manufacturing; our exposure to increased tariffs, trade restrictions or taxes on our products; negative effects on global economic conditions, financial markets and our business as a result of the United Kingdom’s withdrawal from the European Union; violations of our intellectual property rights and our ability to protect our intellectual property against infringement by third parties; risk of losing our competitive advantage; our failure to successfully integrate recent and future acquisitions into our business; our ability to attract and retain key personnel; our restructuring and realignment activities and disruptions to our operations as a result of consolidation of our operations; product defects or problems integrating our products with other vendors’ products; disruptions in the supply of certain key components or other goods from our suppliers; our failure to accurately forecast component and raw material requirements leading to excess inventories or delays in the delivery of our products; production difficulties and product delivery delays or disruptions; our exposure to medical device regulations, which may impede or hinder the approval or sale of our products and, in some cases, may ultimately result in an inability to obtain approval of certain products or may result in the recall or seizure of previously approved products; potential penalties for violating foreign, U.S. federal, and state healthcare laws and regulations; impact of healthcare industry cost containment and healthcare reform measures; changes in governmental regulations affecting our business or products; our failure to implement new information technology systems and software successfully; our failure to realize the full value of our intangible assets; increasing scrutiny and changing expectations from investors, customers, and governments with respect to Environmental, Social and Governance policies and practices; our exposure to the credit risk of some of our customers and in weakened markets; our reliance on third party distribution channels; our reliance on original equipment manufacturer customers; being subject to U.S. federal income taxation even though we are a non-U.S. corporation; changes in tax laws, and fluctuations in our effective tax rates; any need for additional capital to adequately respond to business challenges or opportunities and repay or refinance our existing indebtedness, which may not be available on acceptable terms or at all; our existing indebtedness limiting our ability to engage in certain activities; volatility in the market price for our common shares; and our failure to maintain appropriate internal controls in the future.

Other important risk factors that could affect the outcome of the events set forth in these statements and that could affect the Company’s operating results and financial condition are discussed in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as updated by our future filings with the Securities and Exchange Commission (“SEC”). Such statements are based on the Company’s beliefs and assumptions and on information currently available to the Company. The Company disclaims any obligation to publicly update or revise any such forward-looking statements as a result of developments occurring after the date of this document except as required by law.

About Novanta

Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers (“OEMs”) a competitive advantage. We combine deep proprietary technology expertise and competencies in photonics, vision, and precision motion with a proven ability to solve complex technical challenges. This enables Novanta to engineer core components and sub-systems that deliver extreme precision and performance, tailored to our customers' demanding applications. The driving force behind our growth is the team of innovative professionals who share a commitment to innovation and customer success. Novanta’s common shares are quoted on Nasdaq under the ticker symbol “NOVT.”

More information about Novanta is available on the Company’s website at www.novanta.com. For additional information, please contact Novanta Investor Relations at (781) 266-5137 or InvestorRelations@novanta.com.

NOVANTA INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands of U.S. dollars or shares, except per share amounts)
(Unaudited)

Three Months Ended

April 1,

April 2,

2022

2021

Revenue

$

204,216

$

162,584

Cost of revenue

113,940

93,844

Gross profit

90,276

68,740

Operating expenses:

Research and development and engineering

20,929

18,682

Selling, general and administrative

39,352

31,653

Amortization of purchased intangible assets

7,342

3,575

Restructuring, acquisition, and related costs

(1,630

)

3,731

Total operating expenses

65,993

57,641

Operating income

24,283

11,099

Interest income (expense), net

(3,109

)

(1,408

)

Foreign exchange transaction gains (losses), net

69

(257

)

Other income (expense), net

(545

)

(70

)

Income before income taxes

20,698

9,364

Income tax provision (benefit)

1,878

(1,946

)

Consolidated net income

$

18,820

$

11,310

Earnings per common share:

Basic

$

0.53

$

0.32

Diluted

$

0.53

$

0.32

Weighted average common shares outstanding—basic

35,538

35,279

Weighted average common shares outstanding—diluted

35,781

35,789

NOVANTA INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands of U.S. dollars)
(Unaudited)

April 1,

December 31,

2022

2021

ASSETS

Current Assets

Cash and cash equivalents

$

98,805

$

117,393

Accounts receivable, net

123,759

115,617

Inventories

139,166

125,657

Prepaid expenses and other current assets

13,649

15,158

Total current assets

375,379

373,825

Property, plant and equipment, net

89,652

87,439

Operating lease assets

46,710

48,338

Intangible assets, net

208,455

220,989

Goodwill

475,795

479,500

Other assets

10,173

17,792

Total assets

$

1,206,164

$

1,227,883

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities

Current portion of long-term debt

$

4,975

$

5,097

Accounts payable

72,035

68,514

Accrued expenses and other current liabilities

105,965

110,327

Total current liabilities

182,975

183,938

Long-term debt

412,521

429,361

Operating lease liabilities

43,889

45,700

Other long-term liabilities

32,086

47,593

Total liabilities

671,471

706,592

Stockholders’ Equity:

Total stockholders’ equity

534,693

521,291

Total liabilities and stockholders’ equity

$

1,206,164

$

1,227,883

NOVANTA INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands of U.S. dollars)
(Unaudited)

Three Months Ended

April 1,

April 2,

2022

2021

Cash flows from operating activities:

Consolidated net income

$

18,820

$

11,310

Adjustments to reconcile consolidated net income to net cash provided by operating activities:

Depreciation and amortization

14,044

9,849

Share-based compensation

6,774

6,644

Deferred income taxes

(5,140

)

(968

)

Other

(1,014

)

1,549

Changes in assets and liabilities which (used)/provided cash, excluding effects from business acquisitions:

Accounts receivable

(8,949

)

(15,828

)

Inventories

(14,928

)

675

Other operating assets and liabilities

1,740

10,037

Net cash provided by (used in) operating activities

11,347

23,268

Cash flows from investing activities:

Purchases of property, plant and equipment

(6,308

)

(3,268

)

Payment of contingent consideration related to acquisition of technology assets

(1,470

)

(2,200

)

Other investing activities

957

Net cash provided by (used in) investing activities

(6,821

)

(5,468

)

Cash flows from financing activities:

Repayments under term loan and revolving credit facilities

(11,640

)

(1,345

)

Payments of debt issuance costs

(2,133

)

Payments of withholding taxes from share-based awards

(7,733

)

(18,272

)

Purchase of building under finance lease

(8,743

)

Other financing activities

(523

)

(575

)

Net cash provided by (used in) financing activities

(22,029

)

(28,935

)

Effect of exchange rates on cash and cash equivalents

(1,085

)

(357

)

Increase (decrease) in cash and cash equivalents

(18,588

)

(11,492

)

Cash and cash equivalents, beginning of period

117,393

125,054

Cash and cash equivalents, end of period

$

98,805

$

113,562

NOVANTA INC.
Revenue by Reportable Segment
(In thousands of U.S. dollars)
(Unaudited)

Three Months Ended

April 1,

April 2,

2022

2021

Revenue

Photonics

$

62,782

$

58,493

Vision

62,050

67,636

Precision Motion

79,384

36,455

Total

$

204,216

$

162,584

NOVANTA INC.
Reconciliation of GAAP to Non-GAAP Financial Measures
(In thousands of U.S. dollars)
(Unaudited)

Adjusted Gross Profit and Adjusted Gross Profit Margin by Reportable Segment (Non-GAAP):

Three Months Ended

April 1,

April 2,

2022

2021

Photonics

Gross Profit (GAAP)

$

28,387

$

28,109

Gross Profit Margin (GAAP)

45.2

%

48.1

%

Amortization of intangible assets

664

779

Acquisition fair value adjustments

Adjusted Gross Profit (Non-GAAP)

$

29,051

$

28,888

Adjusted Gross Profit Margin (Non-GAAP)

46.3

%

49.4

%

Vision

Gross Profit (GAAP)

$

25,230

$

26,926

Gross Profit Margin (GAAP)

40.7

%

39.8

%

Amortization of intangible assets

1,257

1,519

Acquisition fair value adjustments

Adjusted Gross Profit (Non-GAAP)

$

26,487

$

28,445

Adjusted Gross Profit Margin (Non-GAAP)

42.7

%

42.1

%

Precision Motion

Gross Profit (GAAP)

$

38,150

$

16,077

Gross Profit Margin (GAAP)

48.1

%

44.1

%

Amortization of intangible assets

1,502

679

Acquisition fair value adjustments

Adjusted Gross Profit (Non-GAAP)

$

39,652

$

16,756

Adjusted Gross Profit Margin (Non-GAAP)

49.9

%

46.0

%

Unallocated Corporate and Shared Services

Gross Profit (GAAP)

$

(1,491

)

$

(2,372

)

Amortization of intangible assets

Employee COVID-19 testing costs

125

1,409

Adjusted Gross Profit (Non-GAAP)

$

(1,366

)

$

(963

)

Novanta Inc.

Gross Profit (GAAP)

$

90,276

$

68,740

Gross Profit Margin (GAAP)

44.2

%

42.3

%

Amortization of intangible assets

3,423

2,977

Acquisition fair value adjustments

Employee COVID-19 testing costs

125

1,409

Adjusted Gross Profit (Non-GAAP)

$

93,824

$

73,126

Adjusted Gross Profit Margin (Non-GAAP)

45.9

%

45.0

%

NOVANTA INC.
Reconciliation of GAAP to Non-GAAP Financial Measures
(Amounts in thousands except per share amounts)
(Unaudited)

Adjusted Operating Income and Adjusted Diluted EPS (Non-GAAP):

Three Months Ended April 1, 2022

Operating

Income

Operating

Margin

Income before

Income Taxes

Income Tax

Provision /

(Benefit)

Effective Tax

Rate

Consolidated

Net Income

Diluted EPS

GAAP results

$

24,283

11.9

%

$

20,698

$

1,878

9.1

%

$

18,820

$

0.53

Non-GAAP Adjustments:

Amortization of intangible assets

10,765

5.2

%

10,765

Restructuring costs

622

0.3

%

622

Acquisition and related costs

(2,252

)

(1.1

)%

(2,252

)

Employee COVID-19 testing costs

125

0.1

%

125

Write-off of unamortized deferred financing costs

624

Foreign exchange transaction (gains) losses, net

(69

)

Tax effect on non-GAAP adjustments

2,232

Non-GAAP tax adjustments

126

Total non-GAAP adjustments

9,260

4.5

%

9,815

2,358

7,457

0.20

Adjusted results (Non-GAAP)

$

33,543

16.4

%

$

30,513

$

4,236

13.9

%

$

26,277

$

0.73

Weighted average shares outstanding - Diluted

35,781

NOVANTA INC.
Reconciliation of GAAP to Non-GAAP Financial Measures
(Amounts in thousands except per share amounts)
(Unaudited)

Adjusted Operating Income and Adjusted Diluted EPS (Non-GAAP):

Three Months Ended April 2, 2021

Operating

Income

Operating

Margin

Income before

Income Taxes

Income Tax

Provision /

(Benefit)

Effective Tax

Rate

Consolidated

Net Income

Diluted EPS

GAAP results

$

11,099

6.8

%

$

9,364

$

(1,946

)

(20.8)

%

$

11,310

$

0.32

Non-GAAP Adjustments:

Amortization of intangible assets

6,552

4.0

%

6,552

Restructuring costs

1,546

1.0

%

1,546

Acquisition and related costs

2,185

1.3

%

2,185

Employee COVID-19 testing costs

1,409

0.9

%

1,409

Foreign exchange transaction (gains) losses, net

257

Tax effect on non-GAAP adjustments

2,424

Non-GAAP tax adjustments

120

Total non-GAAP adjustments

11,692

7.2

%

11,949

2,544

9,405

0.26

Adjusted results (Non-GAAP)

$

22,791

14.0

%

$

21,313

$

598

2.8

%

$

20,715

$

0.58

Weighted average shares outstanding - Diluted

35,789

NOVANTA INC.
Reconciliation of GAAP to Non-GAAP Financial Measures
(In thousands of U.S. dollars)
(Unaudited)

Adjusted EBITDA (Non-GAAP):

Three Months Ended

April 1,

April 2,

2022

2021

Consolidated Net Income (GAAP)

$

18,820

$

11,310

Consolidated Net Income Margin

9.2

%

7.0

%

Interest (income) expense, net

3,109

1,408

Income tax provision (benefit)

1,878

(1,946

)

Depreciation and amortization

14,036

9,849

Share-based compensation

6,774

6,644

Restructuring, acquisition, and related costs

(1,630

)

3,731

Employee COVID-19 testing costs

125

1,409

Write-off of unamortized deferred financing costs

624

Other, net

(148

)

327

Adjusted EBITDA (Non-GAAP)

$

43,588

$

32,732

Adjusted EBITDA Margin (Non-GAAP)

21.3

%

20.1

%

Organic Revenue Growth (Non-GAAP):

Three Months Ended April 2, 2022

Compared to

Three Months Ended April 1, 2021

Reported Revenue Growth/(Decline) (GAAP)

25.6

%

Less: Change attributable to acquisitions

20.2

%

Plus: Change due to foreign currency

2.0

%

Organic Revenue Growth/(Decline) (Non-GAAP)

7.4

%

Net Debt (Non-GAAP):

April 1,

December 31,

2022

2021

Total Debt (GAAP)

$

417,496

$

434,458

Plus: Deferred financing costs

5,714

4,126

Gross Debt

423,210

438,584

Less: Cash and cash equivalents

(98,805

)

(117,393

)

Net Debt (Non-GAAP)

$

324,405

$

321,191

Free Cash Flow (Non-GAAP):

Three Months Ended

April 1,

April 2,

2022

2021

Net Cash Provided by Operating Activities (GAAP)

$

11,347

$

23,268

Less: Purchases of property, plant and equipment

(6,308

)

(3,268

)

Plus: Proceeds from sale of property, plant and equipment

137

Free Cash Flow (Non-GAAP)

$

5,176

$

20,000

Consolidated Net Income (GAAP)

$

18,820

$

11,310

Net Cash Provided by Operating Activities as a Percentage of Consolidated Net Income

60.3

%

205.7

%

Free Cash Flow as a Percentage of Consolidated Net Income

27.5

%

176.8

%

Non-GAAP Financial Measures

Organic Revenue Growth

The Company defines the term “organic revenue” as revenue excluding the impact from business acquisitions, divestitures, product line discontinuations, and the effect of foreign currency translation. The Company uses the related term “organic revenue growth” to refer to the financial performance metric of comparing current period organic revenue with the reported revenue of the corresponding period in the prior year. The Company believes that this non-GAAP financial measure, when taken together with our GAAP financial measures, allows the Company and its investors to better measure the Company’s performance and evaluate long-term performance trends. Organic revenue growth also facilitates easier comparisons of the Company’s performance with prior and future periods and relative comparisons to its peers. The Company excludes the effect of foreign currency translation from these measures because foreign currency translation is subject to volatility and can obscure underlying business trends. The Company excludes the effect of acquisitions and divestitures because these activities can vary dramatically between reporting periods and between the Company and its peers, which the Company believes makes comparisons of long-term performance trends difficult for management and investors. Organic Revenue Growth is also used as a performance metric to determine bonus payments for senior management and employees.

Adjusted Gross Profit and Adjusted Gross Profit Margin

The calculation of Adjusted Gross Profit and Adjusted Gross Profit Margin is displayed in the tables above. Adjusted Gross Profit and Adjusted Gross Profit Margin exclude amortization of acquired intangible assets and inventory fair value adjustments related to business acquisitions because: (1) the amounts are non-cash; (2) the Company cannot influence the timing and amount of future expense recognition; and (3) excluding such expenses provides investors and management better visibility into the underlying trend and performance of our businesses. Additionally, the Company excluded costs directly related to employee COVID-19 testing as these costs are unique to the COVID-19 pandemic and have had a significant impact on the Company’s operating results.

Adjusted Operating Income and Adjusted Operating Margin

The calculation of Adjusted Operating Income and Adjusted Operating Margin is displayed in the tables above. Adjusted Operating Income and Adjusted Operating Margin exclude amortization of acquired intangible assets and inventory fair value adjustments related to business acquisitions, and costs directly related to employee COVID-19 testing for the reasons described for Adjusted Gross Profit and Adjusted Gross Profit Margin above. The Company also excluded restructuring, acquisition, and related costs due to the significant changes that have occurred outside of the Company’s day-to-day business for the reasons described above in the introductory paragraphs of the “Use of Non-GAAP Financial Measures.”

Adjusted Income before Income Taxes

The calculation of Adjusted Income before Income Taxes is displayed in the tables above. The calculation of Adjusted Income before Income Taxes excludes amortization of acquired intangible assets and inventory fair value adjustments related to business acquisitions, costs directly related to employee COVID-19 testing, and restructuring, acquisition and related costs for the reasons described for Adjusted Operating Income and Adjusted Operating Margin above. The Company excludes write-off of unamortized deferred financing costs because they only arise in certain specific situations when the Company’s existing credit agreement is terminated or modified. The Company also excluded foreign exchange transaction gains (losses) from the calculation of Adjusted Income before Income Taxes as the Company cannot fully influence the timing and amount of foreign exchange transaction gains (losses).

Non-GAAP Income Tax Provision/(Benefit) and Effective Tax Rate

The Non-GAAP Income Tax Provision/(Benefit) and Effective Tax Rate are calculated based on the Adjusted Income before Income Taxes by jurisdiction and the applicable tax rates currently in effect for the respective jurisdictions. In addition, the Company excluded significant discrete income tax expenses (benefits) related to releases of valuation allowances, benefits or expenses associated with the completion of tax audits, effects of changes in tax laws, effects of acquisition related tax planning actions on the Company’s effective tax rate, and the income tax effect of non-GAAP adjustments discussed above.

Adjusted Consolidated Net Income

The calculation of Adjusted ConsolidatedNet Income is displayed in the tables above. Because income before income taxes is included in determining ConsolidatedNet Income, the calculation of Adjusted ConsolidatedNet Income also excludes amortization of acquired intangible assets and inventory fair value adjustments related to business acquisitions, costs directly related to employee COVID-19 testing, restructuring, acquisition and related costs, write-off of unamortized deferred financing costs, and foreign exchange transaction gains (losses) for the reasons described for Adjusted Income before Income Taxes. In addition, the Company excluded significant discrete income tax expenses (benefits) related to releases of valuation allowances, benefits or expenses associated with the completion of tax audits, effects of changes in tax laws, effects of acquisition related tax planning actions on the Company’s effective tax rate, and the income tax effect of non-GAAP adjustments discussed above.

Adjusted Diluted EPS

The calculation of Adjusted Diluted EPS is displayed in the tables above. Because ConsolidatedNet Income is used in the calculation of diluted EPS, Adjusted Diluted EPS excludes amortization of acquired intangible assets and inventory fair value adjustments related to business acquisitions, costs directly related to employee COVID-19 testing, restructuring, acquisition and related costs, write-off of unamortized deferred financing costs, foreign exchange transaction gains (losses), significant discrete income tax expenses (benefits) related to releases of valuation allowances, benefits or expenses associated with the completion of tax audits, effects of changes in tax laws, effects of acquisition related tax planning actions on the Company’s effective tax rate, and the income tax effect of non-GAAP adjustments for the reasons described above for Adjusted ConsolidatedNet Income.

Adjusted EBITDA and Adjusted EBITDA Margin

The Company defines Adjusted EBITDA as the income before deducting interest (income) expense, income tax provision (benefit), depreciation, amortization, non-cash share-based compensation, costs directly related to employee COVID-19 testing, restructuring, acquisition and related costs, acquisition fair value adjustments, other non-operating (income) expense items, including foreign exchange transaction (gains) losses, write-off of unamortized deferred financing costs, and net periodic pension costs of the Company’s frozen U.K. defined benefit pension plan for the reasons described above in the introductory paragraphs of the “Use of Non-GAAP Financial Measures.”

Adjusted EBITDA Margin is defined as Adjusted EBITDA as a percentage of Revenue.

In evaluating Adjusted EBITDA and Adjusted EBITDA Margin, you should be aware that in the future the Company may incur expenses that are the same as, or similar to, some of the adjustments in this presentation.

Free Cash Flow and Free Cash Flow as a Percentage of Consolidated Net Income

The Company defines Free Cash Flow as net cash provided by operating activities less cash paid for purchases of property, plant and equipment and plus cash proceeds from sales of property, plant and equipment. Free Cash Flow as a Percentage of ConsolidatedNet Income is defined as Free Cash Flow divided by ConsolidatedNet Income. Management believes these non-GAAP financial measures are important indicators of the Company’s liquidity as well as its ability to service its outstanding debt and to fund future growth.

Net Debt

The Company defines Net Debt as its total debt as reported on the consolidated balance sheet plus unamortized deferred financing costs and less its cash and cash equivalents as of the end of the period presented. Management uses Net Debt to monitor the Company’s outstanding debt obligations that could not be satisfied by its cash and cash equivalents on hand.

Tags: